A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Trial Profile

A Phase 2 Open Label, Multi-Center, Multinational Study Investigating The Efficacy and Safety Of GTx-024 On Advanced, Androgen Receptor-Positive Triple Negative Breast Cancer (AR+ TNBC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs Enobosarm (Primary)
  • Indications Advanced breast cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors GTx
  • Most Recent Events

    • 14 Aug 2017 According to a GTx media release, the Company expects to have top-line results in the third quarter of 2017. This trial has completed the first stage of the two stage trial. Since there was insufficient clinical benefit response (CBR) demonstrated among patients enrolled in the first stage of the trial, the Company has determined that the second and final stage of the trial will not continue.
    • 31 Jul 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2018.
    • 31 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top